Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Allarity Therapeutics ( (ALLR) ).
On December 3, 2025, Allarity Therapeutics, Inc. transitioned Jeffrey S. Ervin from a part-time to a full-time Chief Financial Officer role under a new employment agreement. This agreement includes an annual base salary of $367,700, restricted stock units, and a performance bonus, reflecting the company’s commitment to strengthening its financial leadership.
The most recent analyst rating on (ALLR) stock is a Buy with a $9.25 price target. To see the full list of analyst forecasts on Allarity Therapeutics stock, see the ALLR Stock Forecast page.
Spark’s Take on ALLR Stock
According to Spark, TipRanks’ AI Analyst, ALLR is a Underperform.
Allarity Therapeutics’ overall stock score is low due to significant financial challenges, including no revenue and consistent operational losses. Technical analysis shows a bearish trend with neutral momentum indicators, while valuation metrics are unfavorable with a negative P/E ratio and no dividend yield. These factors collectively suggest a high-risk investment with limited current appeal.
To see Spark’s full report on ALLR stock, click here.
More about Allarity Therapeutics
Allarity Therapeutics, Inc. operates in the biotechnology industry, focusing on developing and commercializing innovative oncology therapeutics.
Average Trading Volume: 378,765
Technical Sentiment Signal: Sell
Current Market Cap: $18.01M
See more data about ALLR stock on TipRanks’ Stock Analysis page.